ArticlePharmacoEconomics2025

Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis.

Luca Prosperini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.